Why did ABEO's EPS miss forecasts in 2024?

Abeona Therapeutics' (ABEO) EPS missed forecasts in 2024, with notable figures from the first three quarters revealing significant deviations from expected values:

1. **Q1 2024**: Abeona Therapeutics reported an EPS of \(-1.16\), which was below the analyst estimate of \(-53\) cents. This indicates a more substantial-than-expected loss for the quarter.
2. **Q2 2024**: The company reported an EPS of \(-26\) cents, which was above the analyst estimate of \(-36\) cents. This suggests that the actual loss was less severe than anticipated.
3. **Q4 2024**: Abeona Therapeutics reported an EPS of $0.50, which was significantly higher than the forecasted loss of $0.35 per share. This indicates a substantial improvement and a significant positive surprise.

Given these figures, it is clear that the primary reason for the EPS miss in 2024 was the significant loss in Q1, which was more severe than anticipated. While the company performed well in Q2 and Q4, the overall performance for the year was negatively impacted by the Q1 results.

|code|Ticker|Name|Date|Estimate EPS|EPS Surprise|market_code|
|---|---|---|---|---|---|---|
|ABEO|ABEO.O|Abeona Therapeutics|2024 Q1|-0.53|-0.63|186|
|ABEO|ABEO.O|Abeona Therapeutics|2024 Q2|-0.36|0.1|186|
|ABEO|ABEO.O|Abeona Therapeutics|2024 Q3|-0.4|-0.23|186|
|ABEO|ABEO.O|Abeona Therapeutics|2024 Q4|-0.34|0.2|186|